Risperidone: clinical safety and efficacy in schizophrenia.
Risperidone: clinical safety and efficacy in schizophrenia.
复制标题
利培酮：精神分裂症的临床安全性和有效性。
作者：
R. Borison;A. Pathiraja;B. Diamond;R. Meibach
利培酮代表了一种独特的药理学强效拮抗血清素和多巴胺受体。在一项随机、平行组、双盲试验中，利培酮与氟哌啶醇和安慰剂在36例急性加重期精神分裂症患者中进行比较，利培酮显示出比氟哌啶醇更快的抗精神病活性起效。利培酮治疗在统计学上上级优于安慰剂，并有优于氟哌啶醇的趋势。利培酮与安慰剂在锥体外系副作用的评估量表上没有差异，但产生的副作用显著低于氟哌啶醇。没有与利培酮使用相关的主要不良反应，但注意到它减少了迟发性运动障碍的体征。这项研究表明，利培酮可能提供了一个上级副作用，并可能更大的疗效，比标准的精神安定药，如氟哌啶醇。
Risperidone represents a unique pharmacology of potent antagonism of both serotonin and dopamine receptors. In a randomized, parallel-group, double-blind trial of risperidone vs. haloperidol and placebo in 36 schizophrenic patients in acute exacerbation, risperidone showed a quicker onset of antipsychotic activity than did haloperidol. Risperidone treatment was statistically superior to placebo, with a trend toward superiority to haloperidol. Risperidone did not differ from placebo on assessment scales of extrapyramidal side effects, but produced significantly less than did haloperidol. There were no major adverse reactions associated with risperidone use, but it was noted to reduce the signs of tardive dyskinesia. This study suggests that risperidone may offer a superior side-effect profile, and possibly greater efficacy, than a standard neuroleptic such as haloperidol.